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Abstract
Chronic wounds are a major burden to overall healthcare
cost and patient morbidity. Chronic wounds affect a large
portion of the US, and billions of healthcare dollars are spent
in their treatment and management. microRNAs (miRNAs)
are small, noncoding double-stranded RNAs that posttranscriptionally downregulate the expression of proteincoding genes. Studies have identified miRNAs involved in all
three phases of wound healing including inflammation, prolif-
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Introduction
Chronic wounds are a significant burden to a large portion of
the population and in the hospital setting, affecting the overall
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eration, and remodeling. Some miRNAs have been demonstrated in vitro with primary keratinocyte wound healing
model and in vivo with mouse wound healing model through
regulation of miRNA expression to affect the wound healing
process. This review updates the current miRNAs involved in
wound healing and discusses the future therapeutic implicaC 2015 IUBMB Life, 67(12):889–
tions and research directions. V
896, 2015

morbidity and mortality of patients. It is estimated that chronic
wounds affect approximately 6.5 million patients in the United
States (1). Moreover, approximately $25 billion is spent annually in the US toward the treatment of chronic wounds (2).
Patients at risk for delayed wound healing include diabetics,
immunocompromised, elderly, and those with impaired venous
and arterial circulation (3). Wound healing involves three
major stages: inflammation, proliferation, and remodeling (4).
Chronic wounds remain locked in the inflammatory stage (5).
Understanding the key regulators of wound healing, including
recently discovered microRNAs (miRNAs), may identify target
therapies to prevent chronic nonhealing wounds.
The majority of our genome consists of nonprotein-coding
DNA. For decades, these regions were considered insignificant,
but the discovery of miRNAs in 1993 changed this paradigm.
miRNAs are nonprotein-coding small endogenous RNAs that
are approximately 21–25 nucleotides in length and are
believed to regulate up to 50% of all protein-coding genes (6).
Their roles are to post-transcriptionally control the expression
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FIG 1

MiRNA biogenesis pathway. In the nucleus, RNA polymerase II-III transcribes miRNA genes, generating long primary transcripts (pri-miRNAs), and the RNase III-type enzyme Drosha further processes the pri-miRNA, yielding a hairpin precursor
miRNA (pre-miRNA). Exportin 5 transports the pre-miRNA from the nucleus into the cytoplasm. The pre-miRNA hairpins are
further processed into unstable miRNA duplex by Dicer. One strand, mature miRNA, in the duplex is incorporated into Ago
protein and forms a complex, the RISC together with Dicer. Once incorporated into a RISC, the mature miRNA regulates the
target genes by destroying the mRNA through direct cleavage or by inhibiting protein synthesis through binding to 30 UTR of
targeting gene.

of protein-coding genes by binding to messenger RNA (mRNA),
leading to degradation or suppression of translation (7,8). miRNAs have been extensively studied in all fields of medicine.
Notably although, the discovery of miRNA influence on wound
healing may change treatment and management of chronic
wounds in the future. The dysregulation of miRNAs may be a
contributing factor to nonhealing wounds. Identification of
miRNAs involved in each phase of wound healing will further
expose potential therapeutic pathways. We here present a
comprehensive review of the current studies on miRNAs in
wound healing along with their implications in wound healing
management.

miRNA Biogenesis
miRNA biogenesis involves several steps (Fig. 1). miRNAs are
first transcribed from DNA segments by RNA polymerase II or
III and capped at the 50 end with a polyA tail, forming a primiRNA (9). Nuclear RNaseIII-type enzyme Drosha (RNASEN)
and DGCR8 (DiGeorge Syndrome Critical Region 8) cleave this
complex into a 60–70 nucleotide long pre-miRNA with a typical stem loop structure (10). The pre-miRNA is then actively
transported out of the nucleus via Exportin-5 (XPO5) (11).
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Once the precursor is in the cytoplasm, RNaseIII-type enzyme
Dicer cuts the hairpin loop that forms the double stranded
miRNA, approximately 21–25 nucleotides in length. One strand
of the miRNA is incorporated into RISC, an RNA-induced
silencing complex (12). The newly formed miRNA–RISC complex works to stop mRNA translation via imperfect base pairing at the 30 untranslated (UTR) region (13). This leads to regulation of target genes via degradation of mRNA or inhibition
of protein translation (14).

miRNA in Wound Healing
miRNAs are present in all types of tissue and regulate a wide
variety of processes at the cellular level including proliferation,
differentiation, and apoptosis (15). Normal skin development is
dependent on a high manifestation of miRNAs and Dicer
enzyme within the epidermis and hair follicles (16).
Skin serves as a primary protective barrier against the
outside environment as well as a form of UV defense, thermoregulation, pigmentation, and means of reducing water loss
(17). Once this barrier is disrupted, wound healing begins.
Wound healing classically involves three phases: inflammation,
proliferation, and remodeling (4). miRNAs act as both agonists
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and antagonists in the process of restoring barrier function of
the skin. Changes in the expression of specific miRNAs during
different phases can be associated with abnormal wound healing (17). With greater understanding of the roles of miRNAs in
each phase of wound healing, we can appreciate how their
dysregulation leads to delayed or impaired wound restoration.
Notably, miRNAs are potentially involved in wound healing at
virtually every step in a highly coordinated manner (Table 1).

Roles of miRNAs in the Inflammatory
Phase
The first phase of wound healing, inflammation, begins immediately after the skin barrier is disrupted and the clotting cascade
is activated. As hemostasis occurs through the establishment of
a fibrin clot, chemokines and cytokines such as platelet derived
growth factor (PDGF), interleukin-1 (IL-1), transforming growth
factor-b (TGF-b), and tumor necrosis factor-a (TNF-a) are
released into the bloodstream. Due to the breach of the protective barrier, the underlying tissue becomes vulnerable to pathogens and the risk of infection increases. Immune cells such as
monocytes and neutrophils are triggered to travel to the wound
via the aforementioned cytokine and chemokine signaling
(55,56). This signaling, along with receptor gene expression, is
just one of many avenues in which miRNAs regulate the inflammatory phase.miR-146a investigation has shown that it is
extensively involved as a negative regulator of inflammation,
specifically in the innate immune system (57). Macrophages are
regulated by miR-146a and miR-155, which promote production of cytokines and growth factors necessary for monocyte
differentiation into macrophages (19,24). Toll-like receptor-4
(TLR-4)-mediated inflammation is regulated by miR-21’s effects
on programmed cell-death protein 4 (PDCD4) expression (21).
Interestingly, miR-146a, miR-155, and miR-21 are reported to
be linked to wound healing processes (27,58). While miRNAs
certainly promote and induce inflammation, they also work to
downregulate and terminate the phase once necessary (24).
Prolongation of the inflammatory phase can lead to tissue damage and prevent proper wound healing, leading to chronic
wounds (59). As the inflammatory phase comes to an end
through the reduction in number of macrophages and neutrophils, the proliferation phase begins.

Roles of miRNAs in the Proliferation
Phase
The proliferation phase commences 2–3 days after injury
occurs and includes the recruitment of fibroblasts to the
wound site to initiate the formation of granulation tissue,
deposition of collagen, glycosaminoglycans, keratinocyte differentiation, epithelialization, and wound contraction (59,60).
Fibroblasts become the main cell type in the wound by the end
of the first week (4). Cytokines have variable effects on the
miRNAs in fibroblasts, such as miR-155, which increases fibro-
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blast migration (29). Fibroblasts excrete collagen and fibronectin to form a new extracellular matrix (ECM), the foundation
of granulation tissue (59). Moreover, miRNAs such as miR-21,
-99, -155, -184, -198, -203, -205, -210, and -483-3p work to
regulate the production, differentiation, and migration of keratinocytes (27,29–32,34,40).
Within the proliferation phase, new blood vessels begin to
form to readily supply the healing area with plentiful oxygen
and nutrients via angiogenesis/neovascularization. This process is vital to fueling the activity of fibroblasts and epithelial
cells. The hypoxic environment stimulates hypoxia-inducible
factor (HIF) to activate genes including vascular endothelial
growth factor (VEGF) and glucose transporter 1 (GLUT1) to
boost angiogenesis (60,61). Hypoxia-sensitive miRNAs including miR-23, -24, -26, -27, -103, -107, -181, -210, and -213 are
transcriptionally controlled by HIF (62). During this phase, the
tissue appears erythematous due to the newly acquired capillary network. Multiple miRNAs are involved in proangiogenic
and antiangiogenic regulation including miR-15b, -16, -17-92,
-126, -130a, -210, -221, -222 -296, -320, -378, and -503
(35–41,43–50,54).
In addition, keratinocytes migrate from the wound edge to
the wound site and begin to proliferate and differentiate to
restore skin integrity—a process that can be inhibited by various miRNAs including miR-198, -203, and -483-3p (31,32,34).
Re-epithelialization and wound contraction then occur as new
epithelial cells migrate over the wound and myofibroblasts
assist in decreasing the wound magnitude through tightening.
Each cell undergoes the process of apoptosis when its purpose
is fulfilled.

Roles of miRNAs in the Remodeling
Phase
When the wound is closed, the remodeling phase begins. This
phase involves adjustment of the ECM, collagen remodeling to
type I from type III collagen, and scar formation in place of the
temporary granulation tissue. Realignment of the tissue along
tension lines occurs, allowing for ideal wound healing. During
this phase, blood vessels to the wound decrease and cellular
activity begins to quiet in preparation for completion. In specific, miR-29a regulates dermal fibroblasts by controlling their
contractility through targeting TABL1 (51). miR-192/215
increases the expression of E-cadherin by repressed translation
of ZEB2 (54), while E-cadherin plays a role in re-establishing
barrier integrity of skin. Of all the phases of wound healing, the
remodeling phase still requires further investigation into discovering the various miRNAs involved in regulation.

miRNAs Regulate in vitro Wound
Healing Processes
Through the use of in vitro primary human keratinocyte
models, studies have demonstrated the roles of miRNAs in
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TABLE 1

miRNAs in wound healing

miRNA

Target

TABLE 1
References

(Continued)

miRNA

Target

References

Inflammation

miR-16

VEGF

(45)

Proinflammatory

miR-20a

MKK3

(46)

miR-140

PDGF receptor

(18)

miR-20b

HIF-1a

(47)

miR-155

SOCS1

(19)

miR-221

c-kit

(48)

miR-222

c-kit

(48)

Anti-inflammatory
miR-16

COX2

(20)

miR-320

IGF-1

(49)

miR-21

PDCD4

(21)

miR-503

CCNE1, cdc25A

(50)

miR-105

TLR2

(22)

Remodeling

miR-125b

TNF-a

(23)

miR-29a

TAB-1

(51)

miR-146a,b

TRAF6, IRAK1, STAT1

(24)

miR-29b

Smads, b-catenin

(52)

miR-203

TNF-a, IL24

(25)

miR-29c

Smads, b-catenin

(53)

miR-223

Mef2c

(26)

miR-192/215

E-cadherin, SIP1

(54)

miR-21

TIMP3, TIAM1

(27)

miR-99

IGF1R, mTOR, AKT1

(28)

miR-155

KGF, FGF-7

(29)

miR-184

Akt

(30)

miR-198

DIAPH1, PLAU, LAMC2

(31)

miR-203

RAN, RAPH1

(32)

miR-205

SHIP2, Rho-ROCK1

(30)

miR-210

E2F3, ISCU 1=2

(33)

miR-483-3p

MK2, MKI67, YAP1

(34)

miR-17-92

TSP-1

(35,36)

miR-126

Spred1, PIK3R2

(37,38)

miR-130a

GAX, HOXA5

(39)

miR-210

EFNA3 (ephrin-A3)

(40)

miR-296

HGS

(41)

miR-378

Fus-1, Sufu

(42)

miR-92a

Integrin-a5

(43)

miR-17

JAK 1

(44)

miR-15b

VEGF

(45)

Proliferation

Pro-angiogenic

Anti-angiogenic
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keratinocyte wound healing. Several noteworthy examples are
mentioned here.

miR-21 and miR-130a
In human HaCaT keratinocytes, miR-21 was upregulated by
TGF-b1, and miR-21 overexpression promoted keratinocyte
migration (27). Conversely, miR-21 knockdown inhibited TGFb1-induced keratinocyte migration, indicating that miR-21 is
critical for TGF-b-driven keratinocyte migration (27). In a
study conducted by Pastar et al., primary human keratinocytes
were transfected with miR-21 or miR-130a expressed using
pSilencer vector. They found that miR-21 and miR-130a overexpression led to suppression and downregulation of LepR and
early growth response factor 3. The luciferase reporter assay
verified LepR as a direct target for miR-21 and miR-130a.
Both miR-21 and miR-130a delayed epithelialization in an
acute human skin wound model (63).

miR-31
Li et al. identified miR-31 as a key regulator for the promotion
of keratinocyte proliferation and migration in wound healing
using human primary keratinocytes. The expression of miR-31
in an in vivo human skin wound-healing model was upregulated in keratinocytes in the inflammatory through proliferation phase at the wound edge. Overexpression of miR-31 in
human primary keratinocytes encouraged proliferation and
migration. Inhibition of miR-31 had opposing effects. In addition, epithelial membrane protein 1 (EMP-1) was identified as
a direct target of miR-31 and silencing of EMP-1 mimicked

Fahs et al.

FIG 2

Potential roles of miRNAs in wound healing. Different miRNAs are potentially involved in promoting or inhibiting wound healing during the three different phases of wound healing.

effects of overexpression of miR-31. Lastly, TGFb2 was found
to upregulate miR-31 expression (64).

miR-99 and miR-100
Jin et al. used human immortal keratinocyte cell lines (HaCaT)
and ectopically transfected miR-99a, miR-99b, miR-100, or control microRNA mimic (Dharmacon Pittsburgh, PA) with DharmaFECT Transfection Reagent 1. This led to a statistically significant downregulation in cell proliferation (measured by MTT
assay) and cell migration (measured by scratch assay and
trans-well assay) as compared to the cells treated with control
mimic. Additionally, the levels of 63 miRNAs were changed
(P < 0.05) (28).

miR-210
Biswas et al. tested the significance of HIF-1a in regulating
E2F3 and cell proliferation in keratinocytes by human HaCaT
keratinocytes. HIF-1a maintenance caused attenuated expression of E2F3, proposing that HIF-1a downregulates E2F3 via a
miR-210-dependent pathway. Ad-VP16-HIF-1a was delivered
to HaCaT keratinocytes under normoxic conditions to force
stabilization of HIF-1a to examine whether HIF-1a stabilization
was necessary for influencing ischemia-inducible miR210
expression. This process resulted in marked induction of miR210 expression, demonstrating that in keratinocytes miR-210
transcription is driven by HIF-1a. Furthermore, downregulation of basal miR-210 levels in keratinocytes significantly
increased cell proliferation. Therefore, it was demonstrated
that in keratinocytes, HIF-1a drives miR-210 expression, which
in turn compromises cell proliferation by targeting E2F3 (40).

New Insights into miRNAs in Skin Wound Healing

miR-483-3p
Bertero et al. investigated miR-483-3p in scratch-injured cultures of human keratinocytes. They demonstrated upregulation of miR-483-3p in wounded normal human keratinocytes
(NHKs). This expression was significantly increased at 15 h
after wounding and reached a peak of induction (6–8-fold)
between 24 and 72 h. Wound beds were fully closed at 24 h
postinjury as visualized by light microscopy. These findings
added to the hypothesis that miR-483-3p plays a role in the
arrest of the wound closure process and its accumulation at
the final stage peaks (34).

miRNAs Regulate in vivo Wound
Healing Processes
Mouse models provide vital insights into the mechanisms and
pathophysiology of cutaneous wound repair. There are several
notable mouse models used in in vivo wound healing processes, including punch biopsies or excisional wounds on the
necks and backs, and full-thickness wounding of mouse tails.
These models compare wound healing through a variety of
wound-inducing mechanisms.

miR-21
Yang et al. studied how miR-21 was upregulated during
wound healing, coincident with the temporal expression pattern of TGF-b1 after 4 mm punch biopsies were made on the
back of mice (27). Knockdown of endogenous miR-21 in mice
through specific antagomir reduced TGF-b1 induced
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keratinocyte migration and re-epithelialization in a scratch
wound-healing assay. Furthermore, overexpression of miR-21
induced TGF-b1 expression and enhanced keratinocyte migration during wound healing (27). These data further suggest
that miR-21 is critical for TGF-b-driven wound healing
process.

through decreased measured wound size. This was due to the
upregulation of vimentin and b3 integrin in transgenic mice, due
to knockdown of miR-378a, leading to fibroblast differentiation
and angiogenesis upregulation ultimately producing enhanced
wound healing (67).

miR-27b

Future Directions and Conclusions

miR-27b was studied in type 2 diabetic db/db and db/1 mice
by Wang et al., and they found that miR-27b expression was
decreased in db/db bone marrow-derived angiogenic cells
(BMACs) (65). Furthermore, they found that miR-27b mimic
rescues impaired BMAC angiogenesis through suppression of
TSP-1, TSP-2, p66(shc), and semaphorin 6A and improved topical cell therapy of diabetic BMACs on diabetic skin wound closure, while normal BMAC therapy with miR-27b inhibition
showed reduced efficacy in wound closure of mice with 6mm
excisional wounds. Overall, these data suggest that local miR27b delivery may improve wound healing in diabetic mice (65).

miR-146a
Xu et al. compared wound healing process in diabetic (db/db)
mice with age-matched nondiabetic heterozygous (db/1) control mice and measured the expression of miRNA-146a and its
target genes before and after 8 mm punch biopsies were taken
on the dorsum of the mice. miR-146a expression was found to
be significantly downregulated in diabetic mouse wounds,
which correlated with increased gene expression of proinflammatory target genes. The diabetic mice displayed impaired
and delayed wound healing compared to nondiabetic mice.
After treating mice with mesenchymal stem cells (MSCs),
increased expression of miR-146a was observed leading to
decreased proinflammatory target gene expression and
improved wound healing. These findings demonstrated that
decreased expression of miR-146a in diabetic wounds may
contribute to wound healing impairment (58).

miR-155
With the creation of punch wounds in mice, Van Sollingen
et al. found an increased expression of miR-155 in wounded
tissue as compared to normal skin. Moreover, miR-155 knockout mice had increased wound closure compared to the wildtype mice. miR-155 knockout mice treated with interleuikin-4
showed an increase expression of finding in inflammatory
zone-1 gene, which is crucial to deposition of type 1 collagen
and the overall wound healing process (66).

miR-378a
Li et al. generated miR-Pirate378a (anti-miR-378a) and miR-378a
transgenic mice and studied rate of wound healing. Through PCR
measurement, miR-Pirate 378a expression was significantly
higher and miR-378a-5p expression significantly lower in the
transgenic mice. After transgenic and wild type mice were subjected to wound healing via cervical dermal punch biopsy, which
left full-thickness excisional wounds around 5 mm on both sides of
the neck, miR-Pirate378a transgenic mice displayed enhanced
wound healing observed on the sixth day as compared to wild type
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While the majority of the human genome is indeed noncoding,
the practical implication of it is just emerging through studies
on miRNAs. miRNAs are likely to regulate multiple aspects of
wound healing process throughout the stages of inflammation,
proliferation and remodeling of damaged skin, as summarized
in Fig. 2. While many miRNAs have been identified, very few
have been demonstrated in vivo. Understanding and identifying ways specific miRNAs regulate wound healing will uncover
the potential new therapeutic targets for wounding healing,
including miRNAs and its targets.
Although hurdles remain, including the actual delivery of
miRNA to target tissues, due to inability to penetrate a lipid
membrane, the delivery of mimic miRNAs or miRNA inhibitors
to tissue has been done using four methods at least: 1) RNA
oligonucleotides conjugated with other lipophilic molecules; 2)
intravenous injection of antagomiRs, which are chemically
modified cholester-conjugated single strand oligonucleotides;
3) the use of locked nucleic acid modified oligonucleotides
(68,69); 4) through expression vectors (68). A clinical trial
investigating the role of the miR-210 gene in chronic wound
healing is currently underway, making science one step closer
to delivering miRNA specific therapies to combat chronic, nonhealing wounds. As research evolves, the ability to utilize target miRNA-based therapy can further individualize treatment
for patients with non-healing wounds and reduce this healthcare burden.

Acknowledgements
This work was supported by Henry Ford Health System Immunology Program Start-up Grant (T71016 and T71017).

References
[1] Sen, C. K., Gordillo, G. M., Roy, S., Kirsner, R., Lambert, L., et al. (2009)
Human skin wounds: a major and snowballing threat to public health and
the economy. Wound Repair Regen. 17, 763–771.
[2] Brem, H., Stojadinovic, O., Diegelmann, R. F., Entero, H., Lee, B., et al. (2007)
Molecular markers in patients with chronic wounds to guide surgical
debridement. Mol. Med. 13, 30–39.
[3] Diegelmann, R. F. and Evans, M. C. (2004) Wound healing: an overview of
acute, fibrotic and delayed healing. Front. Biosci. 9, 283–289.
[4] Stadelmann, W. K., Digenis, A. G., and Tobin, G. R. (1998) Physiology and
healing dynamics of chronic cutaneous wounds. Am. J. Surg. 176, 26S–38S.
[5] Drinkwater, S. L., Smith, A., and Burnand, K. G. (2002) What can wound fluids tell us about the venous ulcer microenvironment? Int. J. Low Extrem.
Wounds 1, 184–190.
[6] Miranda, K. C., Huynh, T., Tay, Y., Ang, Y. S., Tam, W. L., et al. (2006) A
pattern-based method for the identification of MicroRNA binding sites and
their corresponding heteroduplexes. Cell 126, 1203–1217.

Fahs et al.

[7] Ardekani, A. M. and Naeini, M. M. (2010) The role of microRNAs in human
diseases. Avicenna J. Med. Biotechnol. 2, 161–179.
[8] Ha, M. and Kim, V. N. (2014) Regulation of microRNA biogenesis. Nat. Rev.
Mol. Cell. Biol. 15, 509–524.
[9] Gregory, R. I., Chendrimada, T. P., and Shiekhattar, R. (2006) MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol. Biol. 342, 33–47.
[10] Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., et al. (2003) The nuclear RNase III
Drosha initiates microRNA processing. Nature 425, 415–419.
[11] Murchison, E. P. and Hannon, G. J. (2004) miRNAs on the move:
miRNA biogenesis and the RNAi machinery. Curr. Opin. Cell. Biol. 16,
223–229.
[12] Moreno-Moya, J. M., Vilella, F., and Simon, C. (2014) MicroRNA: key gene
expression regulators. Fertil. Steril. 101, 1516–1523.
[13] Bartel, D. P. (2009) MicroRNAs: target recognition and regulatory functions.
Cell 136, 215–233.
[14] Kai, Z. S. and Pasquinelli, A. E. (2010) MicroRNA assassins: factors that regulate the disappearance of miRNAs. Nat. Struct. Mol. Biol. 17, 5–10.
[15] He, L. and Hannon, G. J. (2004) MicroRNAs: small RNAs with a big role in
gene regulation. Nat. Rev. Genet. 5, 522–531.
[16] Yi, R., O’Carroll, D., Pasolli, H. A., Zhang, Z., Dietrich, F. S., et al. (2006) Morphogenesis in skin is governed by discrete sets of differentially expressed
microRNAs. Nat. Genet. 38, 356–362.
[17] Shilo, S., Roy, S., Khanna, S., and Sen, C. K. (2007) MicroRNA in cutaneous
wound healing: a new paradigm. DNA Cell. Biol. 26, 227–237.
[18] Eberhart, J. K., He, X., Swartz, M. E., Yan, Y. L., Song, H., Boling, T.C., et al.
(2008) MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis.
Nat. Genet. 40, 290–298.
[19] Lu, L. F., Thai, T. H., Calado, D. P., Chaudhry, A., Kubo, M., et al. (2009)
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T
cells by targeting SOCS1 protein. Immunity 30, 80–91.
[20] Shanmugam, N., Reddy, M. A., and Natarajan, R. (2008) Distinct roles of
heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for
advanced glycation end products. J. Biol. Chem. 283, 36221–36233.
[21] Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O’Leary, J.
J., et al. (2010) Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol.
11, 141–147.
[22] Benakanakere, M. R., Li, Q., Eskan, M. A., Singh, A. V., Zhao, J., Galicia, J.
C., et al. (2009) Modulation of TLR2 protein expression by miR-105 in
human oral keratinocytes. J. Biol. Chem. 284, 23107–23115.
[23] Xu, N., Brodin, P., Wei, T., Meisgen, F., Eidsmo, L., Nagy, N., et al. (2011)
MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte
Proliferation by Targeting FGFR2. J. Invest. Dermatol. 131, 1521–1529.
[24] Park, H., Huang, X., Lu, C., Cairo, M. S., and Zhou, X. (2015) MicroRNA-146a
and microRNA-146b regulate human dendritic cell apoptosis and cytokine
production by targeting TRAF6 and IRAK1 proteins. J. Biol. Chem. 290,
2831–2841.
[25] Primo, M. N., Bak, R. O., Schibler, B., and Mikkelsen, J. G. (2012) Regulation
of pro-inflammatory cytokines TNFalpha and IL24 by microRNA-203 in primary keratinocytes. Cytokine 60, 741–748.
[26] Johnnidis, J. B., Harris, M. H., Wheeler, R. T., Stehling-Sun, S., Lam, M. H.,
Kirak, O., et al. (2008) Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451, 1125–1129.
[27] Yang, X., Wang, J., Guo, S. L., Fan, K. J., Li, J., et al. (2011) miR-21 promotes keratinocyte migration and re-epithelialization during wound healing.
Int. J. Biol. Sci. 7, 685–690.
[28] Jin, Y., Tymen, S. D., Chen, D., Fang, Z. J., Zhao, Y., et al. (2013) MicroRNA99 family targets AKT/mTOR signaling pathway in dermal wound healing.
PLoS One 8, e64434
[29] Pottier, N., Maurin, T., Chevalier, B., Puissegur, M. P., Lebrigand, K., et al.
(2009) Identification of keratinocyte growth factor as a target of microRNA155 in lung fibroblasts: implication in epithelial–mesenchymal interactions.
PLoS One 4, e6718

New Insights into miRNAs in Skin Wound Healing

[30] Yu, J., Peng, H., Ruan, Q., Fatima, A., Getsios, S., and Lavker, R. M. (2010)
MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase
SHIP2. Faseb J. 24, 3950–3959.
[31] Sundaram, G. M., Common, J. E., Gopal, F. E., Srikanta, S., Lakshman, K.,
et al. (2013) ’See-saw’ expression of microRNA-198 and FSTL1 from a single
transcript in wound healing. Nature 495, 103–106.
[32] Viticchie, G., Lena, A. M., Cianfarani, F., Odorisio, T., AnnicchiaricoPetruzzelli, M., et al. (2012) MicroRNA-203 contributes to skin re-epithelialization. Cell Death Dis. 3, e435
[33] Biswas, S., Roy, S., Banerjee, J., Hussain, S. R., Khanna, S., Meenakshisundaram, G., et al. (2010) Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic
wounds. Proc. Natl. Acad. Sci. USA 107, 6976–6981.
[34] Bertero, T., Gastaldi, C., Bourget-Ponzio, I., Imbert, V., Loubat, A., et al.
(2011) miR-483-3p controls proliferation in wounded epithelial cells. Faseb
J. 25, 3092–3105.
rez, Y., Ferna
ndez-Hernando, C., Yu, J., Gerber, S. A., Harrison, K. D.,
[35] Sua
et al. (2008) Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. USA 105, 14082–14087.
[36] Suarez, Y., Fernandez-Hernando, C., Pober, J. S., and Sessa, W. C. (2007)
Dicer dependent microRNAs regulate gene expression and functions in
human endothelial cells. Circ. Res. 100, 1164–1173.
[37] Wang, S., Aurora, A. B., Johnson, B. A., Qi, X., McAnally, J., et al. (2008)
The endothelial-specific microRNA miR-126 governs vascular integrity and
angiogenesis. Dev. Cell 15, 261–271.
[38] Harris, T. A., Yamakuchi, M., Ferlito, M., Mendell, J. T., and Lowenstein, C.
J. (2008) MicroRNA-126 regulates endothelial expression of vascular cell
adhesion molecule 1. Proc. Natl. Acad. Sci. USA 105, 1516–1521.
[39] Chen, Y. and Gorski, D. H. (2008) Regulation of angiogenesis through a
microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes
GAX and HOXA5. Blood 111, 1217–1226.
[40] Fasanaro, P., D’Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S.,
et al. (2008) MicroRNA-210 modulates endothelial cell response to hypoxia
and inhibits the receptor tyrosine kinase ligand Ephrin-A3. The Journal of
Biological Chemistry 283, 15878–15883.
[41] Wurdinger, T., Tannous, B. A., Saydam, O., Skog, J., Grau, S., et al. (2008)
miR-296 regulates growth factor receptor overexpression in angiogenic
endothelial cells. Cancer Cell 14, 382–393.
[42] Lee, D. Y., Deng, Z., Wang, C. H., and Yang, B. B. (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and
Fus-1 expression. Proc. Natl. Acad. Sci. USA 104, 20350–20355.
[43] Bonauer, A., Carmona, G., Iwasaki, M., Mione, M., Koyanagi, M., et al.
(2009) MicroRNA-92a controls angiogenesis and functional recovery of
ischemic tissues in mice. Science 324, 1710–1713.
[44] Doebele, C., Bonauer, A., Fischer, A., Scholz, A., Reiss, Y., et al. (2010) Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic
function in endothelial cells. Blood 115, 4944–4950.
[45] Hua, Z., Lv, Q., Ye, W., Wong, C. K. A., Cai, G., et al. (2006) MiRNA-directed
regulation of VEGF and other angiogenic factors under hypoxia. PLoS One
1, e116
[46] Pin, A. L., Houle, F., Guillonneau, M., Paquet, E. R., Simard, M. J., and Huot, J.
(2012) miR-20a represses endothelial cell migration by targeting MKK3 and inhibiting p38 MAP kinase activation in response to VEGF. Angiogenesis 15, 593–608.
[47] Lei, Z., Li, B., Yang, Z., Fang, H., Zhang, G. M., et al. (2009) Regulation of
HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 4, e7629
[48] Felli, N., Fontana, L., Pelosi, E., Botta, R., Bonci, D., et al. (2005) MicroRNAs 221
and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit
receptor down-modulation. Proc. Natl. Acad. Sci. USA 102, 18081–18086.
[49] Kuehbacher, A., Urbich, C., and Dimmeler, S. (2008) Targeting microRNA
expression to regulate angiogenesis. Trends Pharm. Sci. 29, 12–15.
[50] Caporali, A., Meloni, M., Vollenkle, C., Bonci, D., Sala-Newby, G. B., et al.
(2011) Deregulation of microRNA-503 contributes to diabetes mellitusinduced impairment of endothelial function and reparative angiogenesis
after limb ischemia. Circulation 123, 282–291.

895

IUBMB LIFE

[51] Ciechomska, M., O’Reilly, S., Suwara, M., Bogunia-Kubik, K., and van Laar,
J. M. (2014) MiR-29a reduces TIMP-1 production by dermal fibroblasts via
targeting TGF-beta activated kinase 1 binding protein 1, implications for systemic sclerosis. PLoS One 9, e115596
[52] Li, Z., Hassan, M. Q., Jafferji, M., Aqeilan, R. I., Garzon, R., Croce, C. M., et
al. (2009) Biological functions of miR-29b contribute to positive regulation of
osteoblast differentiation. J. Biol. Chem. 284, 15676–15684.
[53] van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R.
H., Marshall, W. S., et al. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad.
Sci. USA 105, 13027–13032.
[54] Wang, B., Herman-Edelstein, M., Koh, P., Burns, W., Jandeleit-Dahm, K.,
et al. (2010) E-Cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth
factor-b. Diabetes 59, 1794–1802.
[55] Rot, A. and von Andrian, U. H. (2004) Chemokines in innate and adaptive
host defense: basic chemokinese grammar for immune cells. Annu. Rev.
Immunol. 22, 891–928.
[56] Rodero, M. P. and Khosrotehrani, K. (2010) Skin wound healing modulation
by macrophages. Int. J. Clin. Exp. Pathol. 3, 643–653.
[57] O’Connell, R. M., Rao, D. S., and Baltimore, D. (2012) microRNA regulation
of inflammatory responses. Annu. Rev. Immunol. 30, 295–312.
[58] Xu, J., Wu, W., Zhang, L., Dorset-Martin, W., Morris, M. W., et al. (2012) The
role of microRNA-146a in the pathogenesis of the diabetic wound-healing
impairment: correction with mesenchymal stem cell treatment. Diabetes 61,
2906–2912.
[59] Midwood, K. S., Williams, L. V., and Schwarzbauer, J. E. (2004) Tissue
repair and the dynamics of the extracellular matrix. Int. J. Biochem. Cell.
Biol. 36, 1031–1037.

896

[60] Falanga, V., Zitelli, J. A., and Eaglstein, W. H. (1988) Wound healing. J. Am.
Acad. Dermatol. 19, 559–563.
[61] Brancato, S. K. and Albina, J. E. (2011) Wound macrophages as key regulators of repair: origin, phenotype, and function. Am. J. Pathol. 178,
19–25.
[62] Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., et al.
(2007) A microRNA signature of hypoxia. Mol. Cell. Biol. 27, 1859–
1867.
[63] Pastar, I., Khan, A. A., Stojadinovic, O., Lebrun, E. A., Medina, M. C., et al.
(2012) Induction of specific microRNAs inhibits cutaneous wound healing. J.
Biol. Chem. 287, 29324–29335.
[64] Li, D., Li, X., Wang, A., Meisgen, F., Pivarcsi, A., et al. (2015) MicroRNA-31
promotes skin wound healing by enhancing keratinocyte proliferation and
migration. J. Invest. Dermatol. 135, 1676–1685.
[65] Wang, J. M., Tao, J., Chen, D. D., Cai, J. J., Irani, K., et al. (2014) MicroRNA
miR-27b rescues bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc.
Biol. 34, 99–109.
[66] van Solingen, C., Araldi, E., Chamorro-Jorganes, A., Fernandez-Hernando,
C., and Suarez, Y. (2014) Improved repair of dermal wounds in mice lacking
microRNA-155. J. Cell. Mol. Med. 18, 1104–1112.
[67] Tang, H., Jin, X., Li, Y., Jiang, H., Tang, X., et al. (2014) A large-scale screen
for coding variants predisposing to psoriasis. Nat. Genet. 46, 45–50.
[68] Fasanaro, P., Greco, S., Ivan, M., Capogrossi, M. C., and Martelli, F. (2010)
microRNA: emerging therapeutic targets in acute ischemic diseases. Pharm.
Ther. 125, 92–104.
[69] Weiler, J., Hunziker, J., and Hall, J. (2006) Anti-miRNA oligonucleotides
(AMOs): ammunition to target miRNAs implicated in human disease? Gene
Ther. 13, 496–502.

Fahs et al.

